ARSACS Gene
Overview <table class="infobox infobox-gene">Gene Symbol </td>Full Name </td>Chromosomal Location </td>NCBI Gene ID </td>OMIM </td>Ensembl ID </td>UniProt </td>Protein Name </td>Protein Size </td>N-terminal UBL domain </td>Sacsin repeat region </td>HepA-binding domain </td>C-terminal J-domain </td>
...
ARSACS Gene
Overview <table class="infobox infobox-gene">Gene Symbol </td>Full Name </td>Chromosomal Location </td>NCBI Gene ID </td>OMIM </td>Ensembl ID </td>UniProt </td>Protein Name </td>Protein Size </td>N-terminal UBL domain </td>Sacsin repeat region </td>HepA-binding domain </td>C-terminal J-domain </td>
ARSACS (Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay) encodes sacsin, a large protein involved in cytoskeletal organization, mitochondrial function, and neuronal protection against oxidative stress. First identified in 2000 as the cause of ARSACS, this gene has since been found to play critical roles in maintaining neuronal integrity. The disease is characterized by early-onset spastic ataxia, peripheral neuropathy, and retinal striation, making it an important model for understanding hereditary ataxias and potentially other neurodegenerative conditions[@bouhlal2019].
Protein Structure and Function
Sacsin Domain Architecture Sacsin is one of the largest proteins in the human body, with multiple functional domains:
The sacsin repeat region contains multiple tandem repeats that are unique to this protein and mediate interactions with various cellular components. The J-domain at the C-terminus indicates involvement in the Hsp40/Hsp70 chaperone system, suggesting a role in protein quality control[@thibault2019].
Normal Cellular Functions Cytoskeletal Organization:
Interacts with intermediate filaments (vimentin, nestin)
Helps maintain cytoskeletal integrity in neurons
Supports axonal transport machinery
Localizes to neuronal processes and growth cones[@ridone2021]
Mitochondrial Function:
Participates in mitochondrial dynamics (fusion/fission)
Protects against mitochondrial dysfunction
Helps maintain mitochondrial membrane potential
Supports neuronal energy metabolism[@gerardo2020]
Protein Quality Control:
Chaperone-like activity via Hsp40 domain
May target misfolded proteins for degradation
Protects against proteotoxic stress
Contributes to ubiquitin-proteasome system function[@martin2020]
Oxidative Stress Protection:
Neural cells are protected against reactive oxygen species
Maintains glutathione levels
Supports antioxidant enzyme expression
Protects against ROS-induced cell death
Role in Neurodegenerative Diseases
Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) Clinical Features:
The classic ARSACS phenotype includes:
Early-onset ataxia: Begins in early childhood (1-5 years)Spasticity: Progressive spastic paraplegia affecting gaitPeripheral neuropathy: Demyelinating sensorimotor neuropathyRetinal striation: Characteristic retinal fiber layer striationAdditional features: Scoliosis, foot deformities, dysarthriaDisease Progression:
Symptoms begin in early childhood
Progressive motor impairment over decades
Loss of ambulation typically in third to fourth decade
Variable severity depending on mutation type[@tremblay2022]
Mechanisms:
Loss of sacsin function: Pathogenic variants result in reduced or absent proteinCytoskeletal disruption: Impaired intermediate filament organizationMitochondrial dysfunction: Altered mitochondrial dynamics and functionOxidative stress vulnerability: Reduced protection against ROSAxonal degeneration: Progressive loss of neuronal processes
Potential Roles in Other Neurodegenerative Diseases Alzheimer's Disease:
Sacsin expression may be altered in AD
Potential interactions with tau pathology
Mitochondrial dysfunction is a common feature
Parkinson's Disease:
Possible involvement in alpha-synuclein metabolism
Mitochondrial dysfunction in PD may relate to sacsin function
Other Ataxias:
Overlapping mechanisms with other hereditary ataxias
Shared pathways involving cytoskeletal integrity
Clinical Significance
Diagnosis Clinical Evaluation:
Neurological examination for ataxia and spasticity
Ophthalmologic exam for retinal striation
Nerve conduction studies for neuropathy
Brain MRI for structural abnormalities
Genetic Testing:
Targeted gene panel for hereditary ataxias
Whole exome sequencing for variant identification
Over 150 pathogenic variants identified to date[@parrillob]
Variant Types:
Missense mutations (often in repeat regions)
Nonsense/frameshift mutations (null alleles)
Splice site mutations
Large deletions
Genotype-Phenotype Correlation The specific variant type correlates with disease severity:
Management Current Treatment:
Physical therapy for mobility
Occupational therapy for daily activities
Orthopedic interventions for deformities
Speech therapy for dysarthria
Emerging Therapies:
Gene replacement therapy (AAV vectors)
Small molecule chaperones
Antioxidant therapies
Neuroprotective agents[@lopez2021]
Expression Pattern
Brain Regions Sacsin is expressed throughout the nervous system:
Cerebellum (Purkinje cells, granule cells)
Spinal cord (anterior horn cells)
Dorsal root ganglia
Cerebral cortex
[Hippocampus](/brain-regions/hippocampus)
Cell Type Specificity
Animal Models
Knockout Models Sacsin knockout mice:
Recapitulate key features of human disease
Ataxia and coordination deficits
Retinal degeneration
Motor neuron pathology[@mercier2019]
Zebrafish models:
Morpholino knockdown causes motor deficits
Used for drug screening
More rapid phenotyping possible
Transgenic Models
Express human pathogenic variants
Conditional knockouts for tissue-specific studies
Reporter lines for expression analysis
Research Methods
Molecular Biology
Western blot for protein expression
Immunofluorescence for localization
Co-immunoprecipitation for interactions
RNA-seq for transcriptional changes
Cellular Models
Primary neuron cultures
iPSC-derived neurons
Astrocyte-neuron co-cultures
Functional Assays
Mitochondrial function assays (JC-1, Seahorse)
Oxidative stress tests
Axonal transport analysis
Cytoskeletal integrity evaluation
Signaling Pathways
Sacsin Interaction Network Sacsin
Gene Variation
Pathogenic Variants Over 150 pathogenic variants have been identified:
Missense: Predominantly in repeat regionsNonsense: Truncated proteins, null allelesFrameshift: Loss of functionSplice site: Aberrant splicingLarge deletions: Complete gene lossCommon Polymorphisms
Population-specific variants
Some may be modifiers of disease severity
Therapeutic Approaches
Pharmacological Strategies
Gene Therapy
AAV-vector delivery: CNS-targeted gene replacementAntisense oligonucleotides: Reduce toxic variantsCRISPR-based approaches: Gene editing (preclinical)[@chen2021]Physical Therapy
Balance training
Strength training
Gait training
Assistive devices
See Also
[Sacsin Protein](/proteins/sacsin-protein)
[ARSACS Disease](/diseases/arsacs)
[Hereditary Ataxias](/mechanisms/hereditary-ataxias)
[Spastic Paraplegia](/mechanisms/spastic-paraplegia)
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
Brain Atlas Resources
[Allen Human Brain Atlas - ARSACS](https://human.brain-map.org/microarray/search/show?search_term=ARSACS)
[Allen Cell Type Atlas](https://celltypes.brain-map.org/)
[BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/)
[Allen Mouse Brain Atlas](https://mouse.brain-map.org/)
References
[Bouhlal et al., ARSACS: gene identification to therapy (2019)](https://pubmed.ncbi.nlm.nih.gov/31759102/)
[Gerardo et al., Sacsin and mitochondrial dynamics (2020)](https://pubmed.ncbi.nlm.nih.gov/32060681/)
[Parrillo et al., Molecular genetics of ARSACS (2020)](https://pubmed.ncbi.nlm.nih.gov/32710645/)
[Mercier et al., Sacsin knockout mice (2019)](https://pubmed.ncbi.nlm.nih.gov/31162542/)
[Ridone et al., Sacsin and cytoskeleton (2021)](https://pubmed.ncbi.nlm.nih.gov/34050034/)
[Tremblay et al., Natural history of ARSACS (2022)](https://pubmed.ncbi.nlm.nih.gov/35017123/)
[Martin et al., Sacsin and oxidative stress (2020)](https://pubmed.ncbi.nlm.nih.gov/32229319/)
[Bauer et al., Genotype-phenotype in ARSACS (2019)](https://pubmed.ncbi.nlm.nih.gov/30566473/)
[Diaz et al., Sacsin and mitochondrial fission (2019)](https://pubmed.ncbi.nlm.nih.gov/30658371/)
[Robinson et al., Sacsin and intermediate filaments (2018)](https://pubmed.ncbi.nlm.nih.gov/29243367/)
[Chen et al., Therapeutic strategies for ARSACS (2021)](https://pubmed.ncbi.nlm.nih.gov/34029104/)
[Thibault et al., Sacsin domains and functions (2019)](https://pubmed.ncbi.nlm.nih.gov/30760412/)
Last updated: 2026-03-25 Show full description